US drug approval ignores science's subtleties, experts say.
Waltz
Emily
E
D000911:Antibodies, Monoclonal / Q000009:adverse effects / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D017277:Drug Approval; D007968:Leukoencephalopathy, Progressive Multifocal / Q000209:etiology; D009103:Multiple Sclerosis / Q000628:therapy; D000069442:Natalizumab; D011634:Public Health / Q000592:standards*; D012307:Risk Factors; D012586:Science; D014481:United States; D014486:United States Food and Drug Administration
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000069442:Natalizumab